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Angiotensin II, the main component of the renin-angiotensin system, is 
associated with cardiovascular diseases such as hypertension, vascular 
remodeling and inflammation. Remodeling process results from dysregulation 
of Matrix Metalloproteinases (MMPs) and their tissue inhibitors (TIMPs). MMPs 
are considered as important target genes for angiotensin II. The aim of this 
study was to determine the effects of angiotensin II on MMP-9 and TIMP-1 
production and MMP/TIMP balance in a monocytic cell type. Human 
monocytic U-937 cells were cultured and treated with 100 nM angiotensin II. 
Supernatants were analyzed for MMP-9 and TIMP-1 using ELISA and 
zymography methods. Real-time PCR was utilized to evaluate relative MMP-
9 and TIMP-1 genes expression following treatments. Cytotoxicity potentials of 
treatments were determined by assaying lactate dehydrogenase leakage 
from the cells. Stimulation of the monocytic cells with angiotensin II 
significantly increased MMP-9 and TIMP-1 secretion as measured by ELISA 
(p<0.05). It also augmented gelatinolytic activity of MMP-9 in the conditioned 
media as much as 49% (p<0.05). Incubation of the cells with angiotensin II for 
12 hr increased MMP-9 and TIMP-1 gene expression 2.7 and 1.8 folds, 
respectively (p<0.05). Angiotensin II treatments did not establish significant 
cytotoxic effects. In summary, our data provide further evidences that 
monocytic MMP-9 is a major effector of angiotensin II. It is induced more 
efficiently than TIMP-1 by angiotensin II that leads to MMP/TIMP imbalance. 
Our data also reveal the pivotal participation of these cells in pathological 
cardiovascular remodeling mediated by angiotensin II. 
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The Renin-Angiotensin System (RAS) and 
specially its primary effector, Angiotensin II 
(ANG), have the central role in cardiovascular 
and hemodynamic homeostasis. Not only 




components are also present in various tissues  
and vasculature to serve paracrine and auto-
crine functions by local ANG production. 
ANG can potentially affect all vascular cells 
including endothelial cells, Smooth Muscle 
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Cells (SMCs), fibroblasts, monocyte/ macro-
phages and cardiac myocytes (1). In patho-
logical states, ANG develops hypertension, 
endothelial dysfunction, inflammation and 
cardiovascular remodeling such as athero-
sclerosis and hypertrophy (2). Vascular inflam-
mation is evident in all conditions associated 
with ANG-mediated vascular damage. The 
inflammatory responses of ANG include in-
crease in vascular permeability, recruitment 
of immune cells and tissue remodeling (3). 
Vascular remodeling is associated with per-
manent degradation and reorganization of the 
Extra Cellular Matrix (ECM) scaffold of the 
vessel wall. This process indicates the neces-
sary participation of specialized enzymes 
called Matrix Metalloproteinases (MMPs). In 
the vessel wall, dysregulated functions of 
MMPs cause degradation of basement mem-
brane, ECM and fibrous cap of plaques, that 
lead to impaired endothelial barrier function, 
infiltration of inflammatory cells, migration 
and proliferation of SMCs and rupture of 
atherosclerotic plaques (4). In physiological 
states, activities of MMPs are precisely regu-
lated at the level of transcription, activation of 
precursor zymogen, secretion, and inhibition 
by endogenous inhibitors. Tissue inhibitors of 
metalloproteinases (TIMPs) are specific endo-
genous inhibitors of MMPs that participate in 
controlling the local activities of MMPs in 
tissues (5).  
Extracellular matrix homeostasis is strictly 
tuned by a coordinated balance between the 
expression of MMPs and the expression of 
TIMPs. It has been shown that a perturbation 
in the balance between TIMPs and MMPs is 
associated with pathological turnover of 
extracellular matrix components in numerous 
cardiovascular diseases (6, 7). Major promoters 
of vascular remodeling, e.g. hemodynamic 
stimuli, oxidative stress, inflammatory and 
vasoactive agents regulate MMPs and TIMPs 
genes expression and activation; thereby alter 
MMP/ TIMP balance (4).  
It has been demonstrated that ANG could 
modulate expression of MMPs and TIMPs via 
signaling cascades that are different in cell 
types (8 - 10). Monocytes are important target 
cells of ANG expressing both AT1 and AT2 
receptors. Monocytes-macrophages have sub-
stantial roles in promoting vascular inflam-
mation, foam cell formation and MMP 
secretion (11, 12). 
The present study was designed to invest-
tigate the effects of ANG on the expression 
and secretion of MMP-9 and its inhibitor, 
TIMP-1, from monocytic cells. We further 
determined the contribution of these cells in 
the ANG-mediated MMP-9/TIMP-1 imbalance.  
 
Materials and Methods 
Cell culture 
Human monocytic U-937 cell line was pro-
vided from the cell bank of Pasteur Institute 
of Iran (NCBI). Cells were grown in RPMI-
1640 containing 5% FBS, 100 IU/ml penicil-
lin, and 100 µg/ml streptomycin in humidified 
atmosphere of 5% CO2: 95% air at 37 °C. 
Culture media were renewed three times a 
week. Cells were seeded in 12-well plates at a 
density of 1.0×106 cells/ ml in a low serum 
medium and were treated with either ANG 
(100 nM) or Lipopolysaccharide (LPS)  
(100 ng/ml) (Sigma Chemical Co. St. Louis, 
MO). LPS, a common inducer of monocytes, 
was applied as a positive control in the ex-
periments. After an overnight incubation, con-
ditioned media were centrifuged and cell pel-
lets and supernatants were frozen separately 
at -80 °C. Cell culture reagents were provided 
from Gibco (Invitrogen, USA).  
 
ELISA assay 
To assess the effects of ANG on MMP-9 
and TIMP-1 secretion to the culture media, 
we measured their levels in the culture super-
natants using a commercial sandwich ELISA 
kit (R&D systems, Minneapolis, MN). Pro-




This technique was applied as previously 
described (13). Briefly, samples of conditioned 
media were equally loaded onto Sodium 
Dodecyl Sulfate Polyacrylamide Gel (SDS-
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PAGE) containing 0.1% gelatin type B. 
Electrophoresis was carried out under non-re-
ducing conditions. Gels were washed in 2.5% 
Triton X-100 twice for 30 min and incubated 
in substrate buffer (50 mmolar Tris-HCl,  
5 mmolar CaCl2, 0.01% NaN3, pH 7.6) for  
24 hr at 37 ºC. Gels were stained with 1% 
Coomassie blue R250 for 1 hr and was de-
stained (45% methanol, 10% acetic acid). 
Places of enzymatic activity revealed as clear 
bands over a dark blue field. Finally, gels 
were photographed and analyzed by NIH 
ImageJ software. Data are presented as fold 
change relative to control.  
 
Gene expression analysis 
The expressions of MMP-9 and TIMP-1 
genes in response to ANG treatment were 
analyzed using real-time PCR technique. 
RNA was isolated from the cell pellets 
employing FAST Pure RNA extraction kit 
(Takara bio inc., Japan). One µg of total RNA 
from each sample was used for cDNA synthe-
sis using Primescript RT enzyme (Takara Bio 
Inc., Japan).  
PCR amplification was performed using 
specific primer pairs and Taqman probes 
(Alpha DNA, Montreal, Canada) cited in 
RTPrimer data base with the following 
sequences: MMP-9 forward 5′-ACC TCG 
AAC TTT GAC AGC GAC-3′, reverse 5′-
GAG GAA TGA TCT AAG CCC AGC-3′, 
probe FAM5′-TGC CCG GAC CAA GGA 
TAC AGT TTG TT-3′TAMRA, TIMP-1 
forward 5′-ATC CGG TTC GTC TAC ACC 
CC-3′, reverse 5′-CAG GTA GTG ATG TGC 
AAG AGT CC-3′, probe FAM5′- AGA GTG 
TCT GCG GAT ACT TCC ACA GGT CC-3′ 
TAMRA, GAPDH forward 5′-GTG AAC 
CAT GAG AAG TAT GAC AAC-3′, reverse 
5′-CAT GAG TCC TTC CAC GAT ACC-3′, 
and probe FAM5′-CCT CAA GAT CAT 
CAG CAA TGC CTC CTG-3′TAMRA. Re-
actions were carried out utilizing Rotor-gene 
6000 thermocycler (Corbett research, Austra-
lia).  
Shuttle PCR conditions were as follows: 
initial denaturation at 95 °C for 15 sec follow-
ing 40 cycles of denaturation at 95 °C for  
10 sec and annealing/ extension at 59, 60 and 
62 °C (for TIMP-1, MMP-9 and GAPDH 
respectively) for 25 sec.  
Target genes expressions were normalized 
against GAPDH expression and relative quan-
tification analysis was performed based on 
∆∆Ct calculations. Melting curve analyses 
were also performed by Rotor-gene 6000 soft-




To determine a potential cytotoxicity effect 
of the ANG concentration that was used in 
our experiments, cell supernatants were as-
sayed for Lactate Dehydrogenase (LDH) ac-
tivity using a LDH based cytotoxicity detec-
tion kit (Roche, Germany). Procedures were 




The data are expressed as mean ± SEM of 
four independent determinations and analyzed 
by ANOVA followed by Tukey multiple 
comparison test using SPSS software version 
17.0. P<0.05 was considered as significant. 
 
Results 
To evaluate the effects of ANG on MMP-9 
and TIMP-1 secretion, we benefited from 
ELISA and zymography techniques. As 
shown in figure 1 (A and B), stimulation of 
the cells with ANG for 24 hr resulted in 2.4 
and 1.6 folds increase in MMP-9 and TIMP-1 
levels, respectively (p<0.05). For further con-
firmation of the results, gelatinolytic activities 
of conditioned media were also determined 
(Figure 2). Two bands were detected for each 
sample in zymography analysis. Cultured U-
937 cells constitutively secreted MMP-2 and 
MMP-9 to the incubation medium in treated 
and control groups as revealed by gelatin 
zymography.  
In accordance with ELISA results, ANG 
significantly increased the activity of MMP-9 
in the medium (49%, p<0.05). LPS which was 
applied in the experiments as a positive 
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Real-time PCR technique was used to 
analyze MMP-9 and TIMP-1 genes expres-
sion in response to ANG. The amplicon sizes 
of PCR products with the applied primer pairs 
were 113, 125, and 123 bp for MMP-9, 
TIMP-1, and GAPDH, respectively. As 
shown in figure 3, incubation of cells with 
ANG for 12 hr induced 2.7 and 1.8 folds in-
crease in MMP-9 and TIMP-1 gene expres-
sion respectively (p<0.05). Tm values of amp-
licons found to be 87, 83, and 81.5 °C for 
MMP-9, TIMP-1, and GAPDH, respectively. 
In order to calculate the cyotoxicity per-
centage of ANG in the applied concentration, 
the percentage release of LDH from the 
treated cells was calculated by comparing it to 
the maximum release of LDH achieved by 
lysis of the control cells using a lysis solution. 
Figure 1. A) Measurement of MMP-9  B) and TIMP-1 levels in cell free 
conditioned media by ELISA. 1×106 serum starved cells were seeded in 12-
well plates and treated either with LPS (100 ng/ml) or ANG (100 nmolar) 
for 24 hr. Data are expressed as mean±SEM (n=4). * p<0.05 vs. control. 
ANG=Angiotensin II, LPS= Lipopolysaccharide 
Figure 3. Analysis of MMP-9 and TIMP-1 gene 
expression by real-time PCR. 1.0×106 serum starved 
cells were seeded in 12-well plates and incubated either 
with LPS (100 ng/ml) or ANG (100 nmolar) for 12 hr. 
Gene expression data are expressed relative to control as 
mean±SEM (n=4). * p<0.05 vs. control, # p<0.01 vs. 
control. ANG=Angiotensin II, LPS = Lipopolysac-
charide 
Figure 2. Zymographic determination of MMP-9 in 
culture media of U-937 cells. 1×106 serum starved cells 
were seeded in 12-well plates and treated either with LPS 
(100 ng/ml) or ANG (100 nmolar) for 24 hr. A 
representative zymogram has been shown (upper panel). 
Data are presented relative to control as mean±SEM 
(n=4) following densitometry. * p<0.05 vs. control. 
ANG= Angiotensin II, LPS = Lipopolysaccharide 
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The cytotoxicity percentage was measured 
6.5±0.8% which was not considered signifi-
cantly cytotoxic (p=0.6). 
 
Discussion 
Alteration in MMPs and TIMPs activities 
and the consequent MMPs/ TIMPs imbalance, 
mediates pathological remodelings during 
atherosclerosis, myocardial infarction, left 
ventricular hyperplasia and heart failure as it 
has been shown in animal models. Ischemic 
cardiomyopathies, pressure and volume over-
load as well as neuroendocrine factors such as 
angiotensin II, endothelin 1, TNF-α and TGF-
β can alter MMPs and TIMPs expression in a 
time and cell dependent manner, leading to 
disturbance of MMPs/ TIMPs balance in 
cardiovascular tissues (14).  
It has been demonstrated that application of 
AT1 Receptor Blockers (ARBs), normalize 
MMPs and TIMPs expression and restores 
their normal balance (15). Since in in vivo 
studies, biopsy speciemens have been used, it 
could not be determined how a specific cell 
type contributed to the observed divergent 
patterns of MMP and TIMP expression. In 
this study we investigated the effects of ANG 
on the expression and secretion of MMP-9 
and its tissue inhibitor, TIMP-1, in mono-
cytes. These cells are important target cells of 
ANG and account for a great deal of secreted 
MMPs and TIMPs during cardiovascular 
remodeling (4, 16). We employed monocytic  
U-937 cells that have been used to investigate 
modulation of cytokines and inflammatory 
genes expression and corresponding signaling 
pathways in response to various agents (17). 
Yuan and colleagues used this cell to evaluate 
angiotensin II type 1 receptor blockade to 
inhibit IL-1beta production (18). This cell 
secretes considerable amounts of MMP-9 that 
can be served as a positive control of MMP-9 
secretion.  
In our study, the data obtained from ELISA 
assay, zymography analysis and gene expres-
sion experiments were in accordance in which 
ANG stimulation significantly augmented 
MMP-9 secretion. MMPs are considered as 
inflammatory genes that are induced through 
different signaling cascades in various cell 
types. It has been demonstrated that PKC, 
MAP kinases, and NF-κB signaling cascades 
are major pathways involving in the regula-
tion of MMPs expression. In the promoter 
region of MMP-9, there are binding elements 
for NF-κB, AP-1, Ets-1, and STAT transcrip-
tion factors (19). Earlier studies have demon-
strated that ANG stimulates MMP-1, MMP-3, 
and MMP-9 secretion in SMCs via NF-κB 
and AP-1 activation in a redox sensitive 
manner (8). In cardiac myocytes, ANG signals 
mechanical stress to induce MMP-2 and 
MMP-14 genes expression via JNK-STAT 
pathway (9).  
Luchtefeld and colleagues reported that 
ANG-induced MMP-2 secretion is NADPH 
oxidase-dependent in endothelial cells (10). 
These findings suggest that ANG can induce 
multiple MMPs within the atherosclerotic 
lesion and cardiac tissue which together can 
enhance neo-intima formation, plaque desta-
bilization, hypertrophy, and heart failure. 
Among matrix degrading proteases, MMP-9 
has a profound effect in atherosclerosis devel-
opment and vascular inflammation. Further-
more genetic studies have been shown that 
MMP-9 gene polymorphisms are related to 
the presence and severity of atherosclerosis 
(20). 
Based on our in vitro experiments, ANG 
challenging augmented TIMP-1 production in 
monocytes is revealed by ELISA and real-
time PCR methods. This is in accordance with 
earlier studies that demonstrated the stimu-
latory effect of ANG in fibroblasts, aortic 
smooth muscle cells and heart endothelial 
cells through Ca2+ overload, PKC and STAT3 
activation (21 - 23). 
Zhang and colleagues showed that ANG 
could up-regulate TIMP-1 expression through 
activating STAT3 signaling pathway in 
human senescent cells. This finding indicated 
that ANG II-STAT3-TIMP-1 pathway might 
be involved in the mechanism of sclerosis in 
aging tissues (24). TIMP-1 was increased to 
compensate for the MMP-9 increase in 
٨٤
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response to ANG exposure. This concurrence 
could be interpreted by common binding 
elements in their promoters that respond in 
the same way toward ANG.  
It should be noted that MMP-9, as an 
inflammatory gene, was activated more effi-
ciently than TIMP-1 due to arsenal of inflam-
matory signaling cascades, that were induced 
following ANG treatment. TIMP-1 expression 
was increased to compensate for this MMP-9 
increase, but it did not catch up with the 
MMP-9 increase. Therefore, the balance 
between them shifted toward increased pro-
teolytic activity. This effect can be even more 
exaggerated in diseased tissue and in vivo 
models due to AT1 receptor up-regulation in 
response to inflammatory and hemodynamic 
stimuli (25). 
In conclusion, this study provides further 
evidences that ANG differentially up regu-
lates MMP-9 and TIMP-1 expression in 
monocytes and disturbs protease/ anti- 
protease balance. Dysregulated activity of 
MMP-9 resulted from the monocytic cells 
contributes to pathological remodeling states 
associated with these cells. 
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